TY  - JOUR
PY  - 2024//
TI  - The public health challenge of Δ8-THC and derived psychoactive cannabis products [editorial]
JO  - JAMA journal of the American Medical Association
A1  - Whitehill, Jennifer M.
A1  - Dunn, Kelly E.
A1  - Johnson, Renee M.
SP  - 834
EP  - 836
VL  - 331
IS  - 10
N2  - In this issue of JAMA, a study by Harlow and colleagues found that 11% of US high school seniors (ie, 12th grade) reported using Δ8-tetrahdyrocannabinol (Δ8-THC) in the past 12 months based on a 2023 survey.1 This study is a reminder that there is a diverse set of cannabis products on the market that vary in their legal and regulatory status and potential for harm.2-5 Δ8-THC is a psychoactive cannabinoid that can be derived from hemp.2,3 It was introduced to the retail market in 2018 and there are indications that its use is on the rise.4 There is little regulatory oversight of production and sales of Δ8-THC and some evidence of adverse outcomes after use<p />  <p>Language: en</p>
LA  - en
SN  - 0098-7484
UR  - http://dx.doi.org/10.1001/jama.2024.0801
ID  - ref1
ER  -